Physician profile
Sergio Morello
NPI 1376971556
$10,448.34
in general payments reported to CMS, 2019-2025
21 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $501 · 2021: $435 · 2022: $3,570 · 2023: $1,841 · 2024: $1,596 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,242 · Travel and Lodging: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.04 |
| Travel and Lodging | $872.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $3,358.10 | 2021-2024 | |
| Alcon Vision LLC | $2,476.87 | 2019-2025 | Lensx, Clareon, Rocklatan |
| Abbvie INC. | $955.56 | 2022-2025 | |
| Allergan, INC. | $726.41 | 2019-2021 | |
| New World Medical,INC. | $662.11 | 2024-2025 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Bausch & Lomb Americas INC. | $365.92 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $298.95 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $272.39 | 2021-2025 | Omni Surgical System |
| Harrow Eye, LLC | $226.76 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $212.15 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $189.64 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $176.63 | 2020-2021 | |
| Horizon Therapeutics Plc | $148.13 | 2022-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $125.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $55.51 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $46.48 | 2019-2023 | Iprime Viscodelivery System, Iaccess Precision Blade, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Shire North American Group INC | $41.71 | 2019 | |
| Kala Pharmaceuticals, INC. | $37.19 | 2019 | |
| Rxsight INC | $27.57 | 2022 | |
| Akorn, INC. | $23.05 | 2020 | |
| Dompe US, INC. | $22.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Morello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.